Pralatrexate | NSC 754230;10-Propargyl-10-deazaaminopterin;PDX | DHFR

首页 / 抑制剂/激动剂 / 细胞周期 / DHFR / Pralatrexate

普拉曲沙 /Pralatrexate 99%+

货号：A243480 同义名： NSC 754230;10-Propargyl-10-deazaaminopterin

Pralatrexate is an antifolate, and structurally a folate analog. Its IC50 is < 300 nM in some cell lines.

Pralatrexate 化学结构
CAS号：146464-95-1

Pralatrexate 3D分子结构
CAS号：146464-95-1

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Pralatrexate 纯度/质量文件产品仅供科研

货号：A243480 标准纯度： 99%+ 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Cell,2024. Ambeed. [ A125712 ]; • Cancer Discov., 2024. Ambeed. [ A285925 ]; • JMC, 2024, 67(17): 14974-14985. Ambeed. [ A288696 ]; • JMC, 2024, 67(17): 15061-15079. Ambeed. [ A524399 , A633512 , A144280 , A174613 ]; • EJNMMI Radiopharm. Chem., 2024, 9, 61. Ambeed. [ A1257961 , A622068 ]; 更多 >

DHFR 亚型比较

产品名称	DHFR ↓ ↑	纯度
Pralatrexate	✔	99%+
Pemetrexed disodium	++++ DHFR, Ki: 7.2 nM	99.9%
Pyrimethamine	++ DHFR, IC50: 15.4 nM	98% HPLC
Pemetrexed	++++ DHFR , Ki: 7.2 nM	99+%
Methotrexate	+ hDHFR, IC50: 24 nM	99% (contain ~10%water)
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Pralatrexate 生物活性

靶点

DHFR

描述

Pralatrexate, a folate analogue targeting dihydrofolate reductase, has antitumor activity in non-small-cell lung cancer (NSCLC) ^[3]. Pralatrexate (10-propargyl-10-deazaaminopterin) is an antifolate with improved cellular uptake and retention due to greater affinity for the reduced folate carrier (RFC-1) and folyl-polyglutamyl synthase. In vitro, pralatrexate and bortezomib exhibited concentration- and time-dependent cytotoxicity against a broad panel of T-lymphoma cell lines^[4]. Coadministration of pralatrexate and romidepsin was safe, well tolerated, with 3 DLTs across all schedules (grade 3 oral mucositis × 2; grade 4 sepsis × 1) ^[5].

Pralatrexate 细胞研究

细胞系	浓度	检测类型	检测时间	活动说明	数据源
Chinese hamster R2 cells		Growth inhibition assay	96 h	Growth inhibition of Chinese hamster R2 cells expressing human PCFT4 after 96 hrs by CellTiter-blue assay, IC50=0.057 μM	24111942
human KB cells		Growth inhibition assay	96 h	Growth inhibition of human KB cells expressing human RFC/FRalpha/PCFT after 96 hrs by CellTiter-blue assay, IC50=0.47 nM	24111942

Pralatrexate 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT01626664	Adult T-cell Leukemia-Lymphoma	Phase 2	Completed	-	United States, California ... 展开 >> Cedars-Sinai Medical Center Los Angeles, California, United States, 90048 United States, Florida University of Miami / Sylvester Comprehensive Cancer Center Miami, Florida, United States, 33136 United States, Illinois Northwestern University Chicago, Illinois, United States, 60611 United States, Maryland National Cancer Institute Bethesda, Maryland, United States, 20892 United States, Missouri Washington University School of Medicine Saint Louis, Missouri, United States, 63110 United States, New Jersey Hackensack University Medical Center Hackensack, New Jersey, United States, 07601 United States, New York Montefiore Medical Center Bronx, New York, United States, 10467 Memorial Sloan Kettering New York, New York, United States, 10021 Columbia Presbyterian New York, New York, United States, 10032 Weill Cornell Medical College New York, New York, United States, 10065 Belgium Cliniques Universitaires Saint-Luc Bruxelles, Belgium, 1200 Brazil Hospital Universitario Professor Edgard Santos- UFBA Salvador, Bahia, Brazil, 40110-060 Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo Sao Paulo- SP, Brazil, CEP 05403-000 France CHU de Fort de France Fort De France Cedex, France, BP 632 97261 Hospital Necker Paris, France, 75743 Peru Hospital Nacional Edgardo Rebagliati Martins Lima, Peru, Lima11 Instituto Oncologico Miraflores Lima, Peru, Lima18 United Kingdom Guy's Hospital London, United Kingdom, SE1 9RT Imperial College London, United Kingdom, W2 1PG Sandwell General Hospital West Midlands, United Kingdom, B71 4HJ 收起 <<
NCT01626664	-		Completed	-	-
NCT01482962	-		Completed	-	-

Pralatrexate 参考文献

[1]Marchi E, Paoluzzi L, et al. Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies. Clin Cancer Res. 2010 Jul 15;16(14):3648-58.

[2]Izbicka E, Diaz A, et al. Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers. Cancer Chemother Pharmacol. 2009 Oct;64(5):993-9.

[3]Kelly K, Azzoli CG, Zatloukal P, Albert I, Jiang PY, Bodkin D, Pereira JR, Juhász E, Iannotti NO, Weems G, Koutsoukos T, Patel JD. Randomized phase 2b study of pralatrexate versus erlotinib in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) after failure of prior platinum-based therapy. J Thorac Oncol. 2012 Jun;7(6):1041-8

[4]Marchi E, Paoluzzi L, Scotto L, Seshan VE, Zain JM, Zinzani PL, O'Connor OA. Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies. Clin Cancer Res. 2010 Jul 15;16(14):3648-58

[5]Amengual JE, Lichtenstein R, Lue J, Sawas A, Deng C, Lichtenstein E, Khan K, Atkins L, Rada A, Kim HA, Chiuzan C, Kalac M, Marchi E, Falchi L, Francescone MA, Schwartz L, Cremers S, O'Connor OA. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. Blood. 2018 Jan 25;131(4):397-407

Pralatrexate 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.09mL

0.42mL

0.21mL

10.47mL

2.09mL

1.05mL

20.94mL

4.19mL

2.09mL

Pralatrexate 技术信息

CAS号	146464-95-1
分子式	C₂₃H₂₃N₇O₅
分子量	477.473

别名	NSC 754230;10-Propargyl-10-deazaaminopterin;PDX
运输	蓝冰

存储条件

粉末 Sealed in dry,2-8°C

液体 -20°C:3-6个月-80°C:12个月

溶解度

DMSO: 50 mg/mL(104.72 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验配方

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT01626664	Adult T-cell Leukemia-Lymphoma	Phase 2	Completed	-	United States, California ... 展开 >> Cedars-Sinai Medical Center Los Angeles, California, United States, 90048 United States, Florida University of Miami / Sylvester Comprehensive Cancer Center Miami, Florida, United States, 33136 United States, Illinois Northwestern University Chicago, Illinois, United States, 60611 United States, Maryland National Cancer Institute Bethesda, Maryland, United States, 20892 United States, Missouri Washington University School of Medicine Saint Louis, Missouri, United States, 63110 United States, New Jersey Hackensack University Medical Center Hackensack, New Jersey, United States, 07601 United States, New York Montefiore Medical Center Bronx, New York, United States, 10467 Memorial Sloan Kettering New York, New York, United States, 10021 Columbia Presbyterian New York, New York, United States, 10032 Weill Cornell Medical College New York, New York, United States, 10065 Belgium Cliniques Universitaires Saint-Luc Bruxelles, Belgium, 1200 Brazil Hospital Universitario Professor Edgard Santos- UFBA Salvador, Bahia, Brazil, 40110-060 Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo Sao Paulo- SP, Brazil, CEP 05403-000 France CHU de Fort de France Fort De France Cedex, France, BP 632 97261 Hospital Necker Paris, France, 75743 Peru Hospital Nacional Edgardo Rebagliati Martins Lima, Peru, Lima11 Instituto Oncologico Miraflores Lima, Peru, Lima18 United Kingdom Guy's Hospital London, United Kingdom, SE1 9RT Imperial College London, United Kingdom, W2 1PG Sandwell General Hospital West Midlands, United Kingdom, B71 4HJ 收起 <<
NCT01626664	-		Completed	-	-
NCT01482962	-		Completed	-	-
NCT01482962	Relapsed Peripheral T-Cell Lym... 展开 >>phoma Refractory Peripheral T-Cell Lymphoma 收起 <<	Phase 3	Completed	-	-
NCT02551718	Acute Leukemia of Ambiguous Li... 展开 >>neage Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Adult Acute Myeloid Leukemia Recurrent Childhood Acute Lymphoblastic Leukemia Recurrent Childhood Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia Refractory Adult Acute Lymphoblastic Leukemia Refractory Childhood Acute Lymphoblastic Leukemia 收起 <<	Not Applicable	Recruiting	-	United States, Washington ... 展开 >> Fred Hutch/University of Washington Cancer Consortium Recruiting Seattle, Washington, United States, 98109 Contact: Pamela S. Becker 206-616-1589 pbecker@u.washington.edu Principal Investigator: Pamela S. Becker 收起 <<
NCT03719105	NK-Cell Lymphoma ... 展开 >> NK-Cell Leukemia Peripheral T Cell Lymphoma 收起 <<	Early Phase 1	Not yet recruiting	December 31, 2023	-
NCT01206465	-		Completed	-	-
NCT00024245	Unspecified Adult Solid Tumor,... 展开 >> Protocol Specific 收起 <<	Phase 1	Completed	-	United States, New York ... 展开 >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 收起 <<
NCT01206465	Unspecified Adult Solid Tumor,... 展开 >> Protocol Specific 收起 <<	Phase 1	Completed	-	United States, Nebraska ... 展开 >> UNMC Eppley Cancer Center at the University of Nebraska Medical Center Omaha, Nebraska, United States, 68198-6805 收起 <<
NCT00052442	Lymphoma	Phase 2	Completed	-	United States, New York ... 展开 >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 收起 <<
NCT00004238	Lung Cancer	Phase 2	Completed	-	United States, New York ... 展开 >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 收起 <<
NCT00722553	Carcinoma, Transitional Cell ... 展开 >> Bladder Cancer Bladder Neoplasm 收起 <<	Phase 2	Completed	-	United States, Arizona ... 展开 >> The University of Arizona Health Sciences Center Tucson, Arizona, United States, 85724 United States, Georgia Peachtree Hematology/Oncology Consultants Atlanta, Georgia, United States, 30318 United States, New York University of Rochester Cancer Center Rochester, New York, United States, 14642 United States, Utah University of Utah, Huntsman Cancer Institute Salt Lake City, Utah, United States, 84112 Argentina Centro de Terapia Radiante Cumbres (CAICI) Rosario, Santa Fe, Argentina, 2000 IONC (Instituto Oncológuci de Cordoba) Cordoba, Argentina, X5004BAL Belgium Algemeen Ziekenhuis Middelheim Antwerp, Belgium, 2020 Institut Jules Bordet Brussels, Belgium, 1000 Croatia CH Split Clinic of Oncology and Radiotherapy Split, Croatia, 21000 CHU Zagreb University Hospital Center Rebro in Zagreb Zagreb, Croatia, 10000 Clinic of Oncology and Nuclear Medicine, CH "Sestre Milosrdnice" Zagreb, Croatia, 10000 France Institut Sainte Catherine Avignon, France, 84082 Centre Oscar Lambret Lille Cedex, France, 59020 Centre Hospitalier Rene Dubos Pontoise, France, 95301 Hopital Foch Suresnes, France Institut Gustave Roussy Villejuif Cedex, France, 94 805 Spain Ciutat Sanitari de Vall d'Hebron Barcelona, Spain, 08035 Hospital Del Mar - Barcelona Barcelona, Spain, 8003 Hospital Virgen del Rocio Sevilla, Spain, 41013 收起 <<
NCT00722553	-		Completed	-	-
NCT01129206	-		Completed	-	-
NCT01129206	Adenocarcinoma of the Esophagu... 展开 >>s Adenocarcinomas of the Gastroesophageal Junction Recurrent Esophageal Cancer Squamous Cell Carcinoma of the Esophagus Stage IV Esophageal Cancer 收起 <<	Phase 2	Completed	-	United States, Ohio ... 展开 >> Ohio State University Columbus, Ohio, United States, 43210 收起 <<
NCT00481871	Relapsed or Refractory Lymphop... 展开 >>roliferative Malignancies Hodgkin's Lymphoma Peripheral T-cell Lymphoma B-cell Lymphoma Waldenstrom's Macroglobulinemia 收起 <<	Phase 1 Phase 2	Completed	-	United States, California ... 展开 >> University of California at Los Angeles Los Angeles, California, United States, 90095-7077 Stanford University School of Medicine Stanford, California, United States, 94305 United States, Colorado Rocky Mountain Cancer Center Denver, Colorado, United States, 80218 United States, Illinois University of Chicago Hospital Chicago, Illinois, United States, 60637 United States, Massachusetts Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115-6013 United States, Missouri Washington University School of Medicine St. Louis, Missouri, United States, 63110 United States, Nebraska University of Nebraska Medical Center Omaha, Nebraska, United States, 68198 United States, New Jersey The Cancer Center at Hackensack University Medical Center Hackensack, New Jersey, United States, 07601 United States, New York New York University Hospital New York, New York, United States, 10016 Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10017 United States, Pennsylvania Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111 United States, South Carolina Medical University of South Carolina Charleston, South Carolina, United States, 29425 United States, Texas UT MD Anderson Cancer Center Houston, Texas, United States, 77030 Cancer Therapy & Research Center San Antonio, Texas, United States, 78229-4427 United States, Washington Fred Hutchinson Cancer Research Center Seattle, Washington, United States, 98109 收起 <<
NCT00998946	Lymphoma, B-Cell	Phase 2	Completed	-	United States, California ... 展开 >> Tower Cancer Research Foundation Beverly Hills, California, United States, 90211 United States, Idaho Kootenai Cancer Center Post Falls, Idaho, United States, 83854 United States, Illinois Rush University Medical Center Chicago, Illinois, United States, 60612 United States, Kentucky Owsley Brown Frazier Cancer Center Louisville, Kentucky, United States, 40245 United States, Louisiana Overton Brooks VA Medical Center Shreveport, Louisiana, United States, 71101 United States, Montana Frontier Cancer Center and Blood Institute Billings, Montana, United States, 59102 United States, New York New York University Hospital New York, New York, United States, 10016 United States, Oregon Providence Cancer Center Portland, Oregon, United States, 97225 United States, Tennessee The West Clinic (ACORN) Memphis, Tennessee, United States, 38120 United States, Wisconsin Gundersen Lutheran LaCrosse, Wisconsin, United States, 54601 University of Wisconsin, Paul P. Carbone Comprehensive Cancer Center Madison, Wisconsin, United States, 53705-2275 收起 <<
NCT02013362	Peripheral T-cell Lymphoma	Phase 1 Phase 2	Completed	-	Japan ... 展开 >> National Hospital Organization Nagoya Medical Center Nagoya, Aichi, Japan, 460-0001 National Cancer Center Hospital Chuo, Tokyo, Japan, 104-0045 Okayama University Hospital Okayama,, Japan, 700-8558 收起 <<
NCT00481871	-		Completed	-	-
NCT01336933	-		Completed	-	-
NCT01134341	Cutaneous T-cell Lymphoma ... 展开 >> Mycosis Fungoides Sezary Syndrome Primary Cutaneous Anaplastic Large Cell Lymphoma 收起 <<	Phase 1	Completed	-	United States, California ... 展开 >> Stanford University School of Medicine Stanford, California, United States, 94305 United States, New York Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 United States, Pennsylvania University of Pittsburgh School of Medicine Pittsburgh, Pennsylvania, United States, 15213 United States, Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Italy Ospedale Sant'Orsola - Policlinico Sant'Orsola Bologna, Italy, 40138 收起 <<
NCT01336933	Anaplastic Large Cell Lymphoma... 展开 >> Angioimmunoblastic T-cell Lymphoma Hepatosplenic T-cell Lymphoma Peripheral T-cell Lymphoma 收起 <<	Phase 2	Completed	-	United States, Arizona ... 展开 >> Mayo Clinic in Arizona Scottsdale, Arizona, United States, 85259 United States, California Stanford University Stanford, California, United States, 94305 United States, Georgia Emory University School Of Medicine Atlanta, Georgia, United States, 30308 United States, Illinois University of Chicago Chicago, Illinois, United States, 60637 United States, Massachusetts University of Massachusetts Medical School Worcester, Massachusetts, United States, 01655 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, Missouri Siteman Cancer Center at Washington University Saint Louis, Missouri, United States, 63110 United States, Nebraska UNMC Eppley Cancer Center at the University of Nebraska Medical Center Omaha, Nebraska, United States, 68198-6805 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27710 收起 <<
NCT01118624	Breast Cancer ... 展开 >> Breast Tumors Neoplasms, Breast Cancer of the Breast Human Mammary Carcinoma 收起 <<	Phase 2	Completed	-	United States, Oregon ... 展开 >> Providence Cancer Center Portland, Oregon, United States, 97213 United States, Tennessee The West Clinic Memphis, Tennessee, United States, 38120 Czech Republic Fakultní nemocnice Olomouc Olomouc, Czech Republic, 775 20 Multiscan, s.r.o. Pardubice, Czech Republic, 532 03 Fakultní nemocnice Královské Vinohrady - FNKV Praha, Czech Republic, 100 34 France Centre Lutte Contre le Cancer Val d'Aurelle (CRLC) Montpellier, Cedex 5, France, 34298 Centre Régional de Lutte Contre le Cancer Alexis Vautrin Vandoeuvre, les Nancy Cedex, France, 54511 Centre Georges François Leclerc Dijon Cedex, France, 21079 Centre Léon Bérard Lyon Cedex, France, 69373 Institut Paoli Calmettes Marseille, France, 13273 Institut Jean-Godinot Reims Cedex 09, France, 51056 Hungary University of Debrecen Medical and Health Science Center Debrecen, Hajdú-Bihar, Hungary, 4032 Semmelweis University Budapest Budapest, Hungary, H-1082 National Health Centre of Hungary Budapest, Hungary, H-1145 收起 <<
NCT01118624	-		Completed	-	-
NCT03356678	-		Completed	-	Korea, Republic of ... 展开 >> Samsung Medical Center Seoul, Seoul, Korea, Republic Of, Korea, Republic of, 135-710 81, Irwon-ro, Gangnam-gu, Seoul, Republic of Korea Seoul, Korea, Republic of, 06351 收起 <<
NCT00364923	Peripheral T-cell Lymphoma	Phase 2	Completed	-	-
NCT03161223	Lymphoma, T-Cell	Phase 1 Phase 2	Recruiting	June 30, 2020	United States, New York ... 展开 >> Center for Lymphoid Malignancies at CUMC Recruiting New York, New York, United States, 10019 Contact: Michelle Malanga, MPA Principal Investigator: Owen A O'Connor, M.D., PhD Sub-Investigator: Jennifer E Amengual, M.D. Sub-Investigator: Ahmed Sawas, M.D. Sub-Investigator: Changchun Deng, M.D. Sub-Investigator: Lorenzo Falchi, M.D. Italy University of Bologna Not yet recruiting Bologna, Italy Principal Investigator: Pier Luigi Zinzani, M.D., PhD. Korea, Republic of Samsung Medical Center Not yet recruiting Seoul, Korea, Republic of Principal Investigator: Won Seog Kim, M.D., Ph.D. 收起 <<
NCT01820091	Non-Small Cell Lung Cancer	Phase 1	Withdrawn	April 2015	-
NCT00364923	-		Completed	-	-
NCT00554827	Cutaneous T-cell Lymphoma	Phase 1	Completed	-	United States, California ... 展开 >> City of Hope National Medical Center Duarte, California, United States, 91010 Stanford University School of Medicine Redwood City, California, United States, 94063 United States, Connecticut Yale University School of Medicine New Haven, Connecticut, United States, 06519 United States, Georgia Emory University Atlanta, Georgia, United States, 30322 United States, Massachusetts Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, Missouri Washington University School of Medicine St. Louis, Missouri, United States, 63110 United States, New York Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10017 Columbia University Medical Center New York, New York, United States, 10032 United States, Texas University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77080-4009 United States, Washington Fred Hutchinson Cancer Center Seattle, Washington, United States, 98109 收起 <<
NCT01188876	-		Completed	-	-
NCT01789723	Non Hodgkin's Lymphoma	Phase 1	Withdrawn	March 2015	-
NCT00606502	Non-small Cell Lung Cancer	Phase 2	Completed	-	-
NCT01183065	Head and Neck Cancer	Phase 2	Completed	-	United States, New Jersey ... 展开 >> Memoral Sloan Kettering Cancer Center Basking Ridge, New Jersey, United States United States, New York Memorial Sloan-Kettering Cancer Center @ Suffolk Commack, New York, United States, 11725 Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 Memorial Sloan-Kettering at Mercy Medical Center Rockville Centre, New York, United States Memoral Sloan Kettering Cancer Center@Phelps Memorial Hospital Sleepy Hollow, New York, United States 收起 <<
NCT01183065	-		Completed	-	-
NCT03240211	PTCL CTCL	Phase 1	Recruiting	December 2020	United States, New York ... 展开 >> 51 West 51st Street, Suite 200 Recruiting New York, New York, United States, 10019 Contact: Michelle Malanga 212-326-5731 mm4629@cumc.columbia.edu Italy University of Bologna Not yet recruiting Bologna, Italy Principal Investigator: Pier Luigi Zinzani, MD, PhD Korea, Republic of Samsung Medical Center Not yet recruiting Seoul, Korea, Republic of Principal Investigator: Won Seog Kim, MD, PhD 收起 <<
NCT01178944	Adenocarcinoma of the Gastroes... 展开 >>ophageal Junction Esophageal Undifferentiated Carcinoma Gastric Adenocarcinoma Gastric Squamous Cell Carcinoma Recurrent Esophageal Adenocarcinoma Recurrent Esophageal Squamous Cell Carcinoma Recurrent Gastric Carcinoma Stage IIIB Esophageal Adenocarcinoma Stage IIIB Esophageal Squamous Cell Carcinoma Stage IIIB Gastric Cancer Stage IIIC Esophageal Adenocarcinoma Stage IIIC Esophageal Squamous Cell Carcinoma Stage IIIC Gastric Cancer Stage IV Esophageal Adenocarcinoma Stage IV Esophageal Squamous Cell Carcinoma Stage IV Gastric Cancer Undifferentiated Gastric Carcinoma 收起 <<	Phase 2	Completed	-	United States, New York ... 展开 >> Roswell Park Cancer Institute Buffalo, New York, United States, 14263 Rochester General Hospital Rochester, New York, United States, 14621 收起 <<
NCT01114282	Multiple Myeloma	Phase 1	Completed	-	United States, California ... 展开 >> Stanford University School of Medicine Stanford, California, United States, 94305 收起 <<
NCT02106650	Relapsed Peripheral T-Cell Lym... 展开 >>phoma Refractory Peripheral T-Cell Lymphoma 收起 <<	Phase 2	Recruiting	December 2018	United States, Kansas ... 展开 >> Cancer Center of Kansas Recruiting Wichita, Kansas, United States, 67214 Contact: Shaker Dakhil Principal Investigator: Shaker Dakhil, MD United States, Washington Seattle Cancer Care Alliance Recruiting Seattle, Washington, United States, 98109 Contact: Andrei Shustov Principal Investigator: Andrei Shustov, MD 收起 <<
NCT01178944	-		Completed	-	-
NCT01420679	Peripheral T-cell Lymphoma	Phase 3	Terminated	-	-
NCT03598998	Recurrent Mature T- and NK-Cel... 展开 >>l Non-Hodgkin Lymphoma Recurrent Mycosis Fungoides Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma Refractory Mycosis Fungoides 收起 <<	Phase 1 Phase 2	Not yet recruiting	April 27, 2021	United States, California ... 展开 >> City of Hope Medical Center Not yet recruiting Duarte, California, United States, 91010 Contact: Alex F. Herrera, MD 626-256-4673 ext 62405 aherrera@coh.org Principal Investigator: Alex F. Herrera, MD United States, Nebraska University of Nebraska Medical Center Not yet recruiting Omaha, Nebraska, United States, 68198 Contact: Matthew A. Lunning, MD 402-559-3848 mlunning@unmc.edu Principal Investigator: Matthew A. Lunning, MD United States, New Jersey Hackensack University Medical Center Not yet recruiting Hackensack, New Jersey, United States, 07601 Contact: Tatyana A. Feldman, MD 551-996-4469 Tatyana.Feldman@Hackensackmeridian.org Principal Investigator: Tatyana A. Feldman, MD 收起 <<
NCT03349333	Refractory Peripheral T-Cell L... 展开 >>ymphoma Relapsed T-Cell Lymphoma 收起 <<	Phase 3	Active, not recruiting	March 30, 2019	China ... 展开 >> Beijing Cancer Hospital Beijing, China, 100142 收起 <<
NCT01947140	Lymphoid Malignancies ... 展开 >> Multiple Myeloma Lymphoma Hodgkin Lymphoma Non-hodgkin Lymphoma 收起 <<	Phase 1 Phase 2	Recruiting	December 2018	United States, New York ... 展开 >> Columbia University Medical Center Recruiting New York, New York, United States, 10019 Contact: Renee Lichtenstein 212-326-5720 rl2619@cumc.columbia.edu Principal Investigator: Jennifer E Amengual, MD 收起 <<
NCT03355768	Lymphoma, T-Cell, Peripheral	Phase 3	Not yet recruiting	January 2020	United States, New York ... 展开 >> Center for Lymphoid Malignancies at CUMC Not yet recruiting New York, New York, United States, 10019 Contact: Michelle Malanga, MPA 212-326-5731 mm4629@cumc.columbia.edu 收起 <<
NCT00606502	-		Completed	-	-
NCT02594267	Peripheral T-Cell Lymphoma (PT... 展开 >>CL) 收起 <<	Phase 1	Recruiting	December 2018	United States, Washington ... 展开 >> Seattle Cancer Care Alliance/University of Washington Recruiting Seattle, Washington, United States, 98109 Contact: Andrei Shustov, MD Principal Investigator: Andrei Shustov, MD 收起 <<
NCT01188876	Ovarian Cancer ... 展开 >> Fallopian Tube Cancer Peritoneal Cancer 收起 <<	Phase 1 Phase 2	Completed	-	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 收起 <<
NCT01532011	Advanced Cancers ... 展开 >> Solid Tumors 收起 <<	Phase 1	Completed	-	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT03150602	Peripheral T Cell Lymphoma ... 展开 >> Progression, Disease 收起 <<	Phase 4	Recruiting	December 31, 2020	Taiwan ... 展开 >> Ntional Taiwan University Hospital Recruiting Taipei, Taiwan, 100 Contact: Bor-Sheng Ko, PhD 886-23123456 ext 63576 kevinkomd@gmail.com Contact: Brook Chung, MSc 886-87297521 brook.chung@mundipharma.com.tw Principal Investigator: Bor-Sheng Ko, PhD 收起 <<

普拉曲沙 /Pralatrexate 99%+

Pralatrexate 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Pralatrexate 质控信息

Pralatrexate 生物活性

Pralatrexate 细胞研究

Pralatrexate 临床研究

Pralatrexate 参考文献

Pralatrexate 实验方案

Pralatrexate 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

普拉曲沙 /Pralatrexate 99%+

Pralatrexate 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Pralatrexate 质控信息

Pralatrexate 生物活性

Pralatrexate 细胞研究

Pralatrexate 临床研究

Pralatrexate 参考文献

Pralatrexate 实验方案

Pralatrexate 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Pralatrexate 纯度/质量文件产品仅供科研